Profile data is unavailable for this security.
About the company
BeyondSpring Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to improve clinical outcomes for patients with high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in non-small cell lung cancer (NSCLC) and a range of cancer indications. The Company’s mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering an approach to resensitizing tumors to checkpoint inhibitors. It also has a pipeline of immuno-oncology product candidates, BPI-002 program, which is based on an oral small molecule agent that increases T-cell co-stimulation; BPI-003 program, which is based on a small molecule inhibitor of IKK, a protein kinase, and BPI-004 program, which is focused on a small molecule that induces the production of neo-antigens by tumor cells, allowing tumors containing no immune cells to be infiltrated by the immune system.
- Revenue in USD (TTM)0.00
- Net income in USD-7.83m
- Incorporated2014
- Employees40.00
- LocationBeyondspring Inc100 Campus DriveWest Side, 4Th Floor, Suite 410FLORHAM PARK 07932United StatesUSA
- Phone+1 (646) 528-4184
- Websitehttps://www.beyondspringpharma.com/en/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Estrella Immunopharma Inc | 0.00 | -13.50m | 51.70m | -- | -- | -- | -- | -- | -0.3697 | -0.3697 | 0.00 | -0.2605 | 0.00 | -- | -- | -- | -371.99 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Mink Therapeutics Inc | 0.00 | -12.36m | 51.82m | 23.00 | -- | -- | -- | -- | -3.03 | -3.03 | 0.00 | -2.94 | 0.00 | -- | -- | 0.00 | -110.62 | -144.86 | -1,640.97 | -870.32 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 51.98 | -- | -- | -- |
| Tevogen Bio Holdings Inc | 0.00 | -31.42m | 52.37m | 18.00 | -- | -- | -- | -- | -0.2138 | -0.2138 | 0.00 | -0.0396 | 0.00 | -- | -- | 0.00 | -706.86 | -- | -- | -- | -- | -- | -- | -- | -- | -231.10 | -- | -- | -- | -- | 83.01 | -- | -- | -- |
| Instil Bio Inc | 0.00 | -75.08m | 52.76m | 14.00 | -- | 0.4382 | -- | -- | -11.39 | -11.39 | 0.00 | 17.76 | 0.00 | -- | -- | 0.00 | -31.00 | -34.59 | -32.06 | -36.59 | -- | -- | -- | -469,515.20 | -- | -19.23 | 0.4127 | -- | -- | -- | 52.50 | -- | 116.55 | -- |
| Tscan Therapeutics Inc | 8.42m | -142.60m | 53.02m | 146.00 | -- | 0.3681 | -- | 6.29 | -1.12 | -1.12 | 0.066 | 2.54 | 0.0276 | -- | -- | 43,417.53 | -46.73 | -38.91 | -51.63 | -43.93 | -- | -- | -1,692.96 | -735.59 | -- | -- | 0.1837 | -- | -86.62 | -- | -42.91 | -- | 25.13 | -- |
| Metagenomi Therapeutics Inc | 30.91m | -88.74m | 54.42m | 124.00 | -- | 0.3051 | -- | 1.76 | -2.39 | -2.39 | 0.8308 | 4.75 | 0.102 | -- | 39.91 | 153,034.70 | -29.27 | -- | -33.42 | -- | -- | -- | -287.06 | -- | -- | -- | 0.00 | -- | 16.84 | -- | -14.36 | -- | -- | -- |
| Grace Therapeutics, Inc | 0.00 | -7.82m | 54.62m | 32.00 | -- | 0.7939 | -- | -- | -0.5851 | -0.5851 | 0.00 | 4.45 | 0.00 | -- | -- | -- | -11.85 | -24.13 | -12.22 | -25.07 | -- | -- | -- | -48,136.22 | -- | -- | 0.00 | -- | -- | -- | 25.56 | -- | -- | -- |
| Kazia Therapeutics Ltd (ADR) | 80.80k | -14.67m | 55.16m | 12.00 | -- | -- | -- | 682.70 | -12.31 | -12.31 | 0.0563 | -3.63 | 0.0083 | -- | 0.0571 | -- | -149.76 | -64.49 | -- | -99.77 | -- | -- | -18,159.65 | -573.31 | -- | -- | -- | -- | -95.09 | 11.58 | 22.69 | -- | -- | -- |
| Beyondspring Inc | 0.00 | -7.83m | 57.43m | 40.00 | -- | -- | -- | -- | -0.1942 | -0.0148 | 0.00 | -0.788 | -- | -- | -- | 0.00 | -- | -61.84 | -- | -81.30 | -- | -- | -- | -6,633.90 | -- | -- | -- | -- | -- | -- | 35.26 | -- | 123.69 | -- |
| PMV Pharmaceuticals Inc | 0.00 | -82.71m | 57.47m | 63.00 | -- | 0.473 | -- | -- | -1.58 | -1.58 | 0.00 | 2.28 | 0.00 | -- | -- | 0.00 | -46.29 | -21.46 | -49.90 | -22.32 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 14.87 | -- | 43.14 | -- |
| RetinalGenix Technologies Inc | 0.00 | -2.67m | 59.54m | 0.00 | -- | -- | -- | -- | -0.1455 | -0.1455 | 0.00 | -0.1168 | 0.00 | -- | -- | -- | -5,576.42 | -14,417.91 | -- | -- | -- | -- | -- | -- | -- | -684.26 | -- | -- | -- | -- | -106.65 | -- | -- | -- |
| Fractyl Health Inc | 3.00k | -122.20m | 62.99m | 107.00 | -- | -- | -- | 20,996.63 | -2.27 | -2.27 | 0.00006 | -0.024 | 0.00002 | -- | -- | 28.04 | -101.33 | -78.52 | -118.18 | -97.44 | 100.00 | -- | -4,073,233.00 | -122,747.90 | -- | -31.40 | 1.12 | -- | -22.50 | -- | 25.29 | -- | 78.65 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 574.23k | 1.40% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 534.30k | 1.30% |
| Geode Capital Management LLCas of 30 Sep 2025 | 315.48k | 0.77% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 179.93k | 0.44% |
| BlackRock Financial Management, Inc.as of 30 Sep 2025 | 90.54k | 0.22% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2025 | 70.78k | 0.17% |
| Tanaka Capital Management, Inc.as of 30 Sep 2025 | 26.30k | 0.06% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 11.60k | 0.03% |
| BlackRock Investment Management LLCas of 30 Sep 2025 | 11.46k | 0.03% |
| Merrill Lynch, Pierce, Fenner & Smith, Inc. (Invt Mgmt)as of 30 Sep 2025 | 7.50k | 0.02% |
